INAL RESEARCH Effectiveness of next-generation sequencing for patients with advanced non-small-cell lung cancer: a population-based registry study

被引:5
|
作者
Kang, D. -W. [1 ]
Park, S. -K. [2 ]
Yu, Y. L. [3 ]
Lee, Y. [4 ]
Lee, D. H. [5 ]
Kang, S. [3 ,6 ,7 ,8 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, Suwon, South Korea
[2] Catholic Univ Korea, Coll Pharm, Bucheon, South Korea
[3] Natl Canc Ctr, Ctr Gynecol Canc, Res Inst & Hosp, Goyang, South Korea
[4] Natl Canc Ctr, Dept Internal Med, Goyang, South Korea
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea
[6] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, Goyang, South Korea
[7] Natl Canc Ctr, Res Inst & Hosp, Ctr Gynecol Canc, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
[8] Natl Canc Ctr, Grad Sch Canc Sci & Policy, Dept Canc Control & Policy, 323 Ilsan Ro, Goyang Si, Gyeonggi Do, South Korea
关键词
next-generation sequencing; single-gene testing; non-small-cell lung cancer; distant metastasis; real-world evidence;
D O I
10.1016/j.esmoop.2023.102200
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Despite the growing use of next-generation sequencing (NGS) in the management of advanced non-smallcell lung cancer (NSCLC), there is little evidence that its use leads to improved clinical outcomes. This study aimed to compare the effectiveness of NGS with that of single-gene testing (SGT) alone in patients with advanced NSCLC. Materials and methods: This was a retrospective cohort study conducted on patients diagnosed with advanced lung adenocarcinoma between 2017 and 2018 from a nationwide, population-based database. We identified patients who had SGT exclusively (SGT group) or underwent upfront NGS or NGS following SGT as an initial evaluation (NGS group). Patients were followed up until death or the end of the study (31 December 2019). The adjusted hazard ratio (aHR) for death was estimated using the Cox proportional hazards model. The factors affecting the adoption of NGS were identified. Results: Of 8566 patients diagnosed with advanced lung adenocarcinoma, 402 and 6932 patients were assigned to the NGS and SGT groups, respectively. More NGS was carried out in younger patients, those with higher incomes, and those living in urban areas. After balancing these confounders through matching, no difference was observed in the median overall survival and risk of death between the NGS and SGT groups [18.5 versus 19.7 months, log-rank P 1/4 0.783; aHR 0.98, 95% confidence interval (CI) 0.84-1.14, respectively]. Only in a subgroup for whom epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) inhibitors were not indicated, NGS was associated with better survival outcomes (14.1 versus 9.0 months, log-rank P 1/4 0.006; aHR 0.82, 95% CI 0.69-0.97). Conclusions: In the real world, NGS for all-comers in patients with advanced NSCLC did not increase survival outcomes. When health care resources to support equal access to NGS are limited, upfront SGT followed by NGS may be a more efficient strategy
引用
收藏
页数:7
相关论文
共 50 条
  • [41] Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
    Yap, Timothy A.
    Popat, Sanjay
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2014, 7 : 285 - 295
  • [42] Next-Generation Sequencing Implementation in Non-Small Cell Lung Cancer Molecular Diagnosis
    Clave, S.
    Bellosillo, B.
    Salido, M.
    Tagmouti, G.
    Taus, A.
    Rocha, P.
    Hardy-Werbin, M.
    Moliner, L.
    Riera, X.
    Fernandez-Rodriguez, C.
    Arriola, E.
    Pijuan, L.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S783 - S783
  • [43] Therapeutic strategy for non-small cell lung cancer in the next-generation sequencing era
    Hayashi, Ryuji
    RESPIRATORY INVESTIGATION, 2021, 59 (01) : 1 - 2
  • [44] Clinical applications of a next-generation sequencing panel in non-small cell lung cancer
    Rijavec, E.
    Genova, C.
    Barletta, G.
    Biello, F.
    Maggioni, C.
    Dal Bello, M. G.
    Truini, A.
    Coco, S.
    Vanni, I.
    Alama, A.
    Grossi, F.
    ANNALS OF ONCOLOGY, 2015, 26 : 86 - 87
  • [45] Next-Generation Sequencing of Liquid-Based Cytology Non-Small Cell Lung Cancer Samples
    Reynolds, Jordan P.
    Zhou, Yaolin
    Jakubowski, Maureen A.
    Wang, Zhen
    Brainard, Jennifer A.
    Klein, Roger D.
    Farver, Carol F.
    Almeida, Francisco A.
    Cheng, Yu-Wei
    CANCER CYTOPATHOLOGY, 2017, 125 (03) : 178 - 187
  • [46] Mutation analysis of endometrial cancer in a population-based study by targeted next-generation sequencing
    Chen, Maxine
    Crous-Bou, Marta
    Downing, Michael J.
    Busch, Evan L.
    Glass, Kimberley
    Prescott, Jennifer
    Mutter, George L.
    De Vivo, Immaculata
    CANCER RESEARCH, 2017, 77
  • [47] The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable EGFR Variants in Non-Small-Cell Lung Cancer
    Szpechcinski, Adam
    Moes-Sosnowska, Joanna
    Skronska, Paulina
    Lechowicz, Urszula
    Pelc, Magdalena
    Szolkowska, Malgorzata
    Rudzinski, Piotr
    Wojda, Emil
    Maszkowska-Kopij, Krystyna
    Langfort, Renata
    Orlowski, Tadeusz
    Sliwinski, Pawel
    Polaczek, Mateusz
    Chorostowska-Wynimko, Joanna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (14)
  • [48] Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practice
    Garinet, Simon
    Lupo, Audrey
    Denize, Thomas
    Loyaux, Romain
    Timsit, Sarah
    Gazeau, Benoit
    Fabre, Elizabeth
    Maaradji, Zineb
    Gibault, Laure
    Giroux-leprieur, Etienne
    Duchemann, Boris
    Monnet, Isabelle
    Jouveshomme, Stephane
    Aldea, Mihaela
    Besse, Benjamin
    Le Pimpec-barthes, Francoise
    Leroy, Karen
    Wislez, Marie
    Blons, Helene
    PATHOLOGY, 2024, 56 (05) : 702 - 709
  • [49] Original Research Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer
    Lee, Kyoungmin
    Kim, Deokhoon
    Yoon, Shinkyo
    Lee, Dae Ho
    Kim, Sang-We
    EUROPEAN JOURNAL OF CANCER, 2021, 148 : 202 - 210
  • [50] Biomarker Testing for Advanced Lung Cancer by Next-Generation Sequencing in Elderly Patients
    Basbus, L.
    Minatta, J. N.
    Ferreira, Y.
    Antivero, A.
    Pandolfi, J.
    Garcia Rivello, H.
    Dalurzo, M.
    Lupinacci, L.
    Jauk, F.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1035 - S1035